J&J wins FDA nod for multiple myeloma therapy

2026-03-05 14:37:33 ET More on Johnson & Johnson Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) Most and least shorted mid-to mega-cap healthcare stocks in February FDA reportedly eyeing staff bonuses to accelerate drug reviews Read the full article on Seeking Alpha For further details see: J&J wins FDA nod for multiple myeloma therapy